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Abstract
Quantitative systems pharmacology (QSP) is a quantitative and mechanistic platform describing the phenotypic interaction
between drugs, biological networks, and disease conditions to predict optimal therapeutic response. In this meta-analysis
study, we review the utility of the QSP platform in drug development and therapeutic strategies based on recent publications (2019–2021). We gathered recent original QSP models and described the diversity of their applications based on
therapeutic areas, methodologies, software platforms, and functionalities. The collection and investigation of these publications can assist in providing a repository of recent QSP studies to facilitate the discovery and further reusability of QSP
models. Our review shows that the largest number of QSP efforts in recent years is in Immuno-Oncology. We also
addressed the benefits of integrative approaches in this field by presenting the applications of Machine Learning methods
for drug discovery and QSP models. Based on this meta-analysis, we discuss the advantages and limitations of QSP models
and propose fields where the QSP approach constitutes a valuable interface for more investigations to tackle complex
diseases and improve drug development.
Keywords Systems biology  Quantitative systems pharmacology  Predictive models  Machine learning 
Immuno-oncology  Immunotherapy

Introduction
QSP and its growing role in drug development
Human cell biology is governed by complex networks of
interactions between molecular structures, signaling pathways, and epigenetic remodeling in which the multiscale
system governs the cell’s functionality. However, these
networks and their inter-layer connections can become
corrupted due to perturbations, leading to various diseases
[1]. Drug development is indispensable to modern medicine; however, bringing drugs to the market is often
compromised for several reasons, including lack of
understanding of drug behavior at the whole system level
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and adverse side effects [2]. To understand the mechanism
of disease networks, identify novel drug targets, and
develop effective therapies requires studying individual
components such as genes, RNA, or proteins as dynamic
systems across scales [3]. Understanding these biological
processes has been revolutionized with the development of
high-throughput technologies and the accumulation of
biomedical data; however, these data types demand integrative and dynamics-driven approaches to comprehend
dataset repositories and accelerate novel discoveries.
Another complexity to consider is drug-target and drugdrug interactions and their consequences at the system
level.
Systems biology aims to address these complexities by
understanding biological processes at the molecular and
cellular system levels [3]. Quantitative systems pharmacology (QSP) stems from system biology and integrates
pharmacological aspects with systems modeling to identify
and design safer and more effective drug therapies. QSP
was defined in 2011 in a National Institutes of Health white
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paper based on workshops and discussions with experts
from academia, government, and industry [4–8].
One of the challenges for drug development is the
increasing cost of drug developments and approvals—it
costs from $1.2 to $4 billion and requires upwards of
10 years to develop and introduce a new drug [9–11]. QSP
addresses some of these challenges by providing integrative approaches to determine mechanisms of action of the
new and existing drugs, maximize therapeutic benefit,
minimize toxicity and implement a procedure to improve
individual patients’ health [7, 12]. QSP uses mechanistic
mathematical models to characterize dynamic interplays
between a drug and physiopathology to explore the system
at multiple scales of biological organization (molecular,
cellular, organ-level networks). Incorporating mechanistic
multi-scale systems aspects to classical pharmacometrics
through QSP can enable novel drug target predictions,
detailed studies of mechanisms of action and safety, biomarker identification, optimization of doses or regimens,
compound selection, decision making, and responses considering various treatment variables [12, 13]. QSP, while
relatively new, complements other modeling approaches
widely adopted for preclinical and clinical studies,
including the quantification of drug behavior in the body
[14]. These tools include:
Pharmacokinetics (PK) focuses on studying the timecourse of drugs’ absorption, distribution, metabolism, and
excretion (ADME; e.g., dose-concentration relationships).
Pharmacodynamics (PD) examines the biological
effects of drugs and their mechanisms of action (e.g.,
concentration-effect relationships) on humans, animals,
microorganisms, or combinations of organisms (e.g.,
infection) [15].
Pharmacokinetic/pharmacodynamic (PK/PD) modeling
connects PK and PD to facilitate the prediction of the time
course of drug effects that result from a specific dosing
regimen [14, 16–18]. Systems pharmacology is already
widely used in the pharmaceutical industry, focusing on
PK/PD modeling, predicting dose-exposure responses, and
evaluating market potential [19]. This modeling assists in
gaining mechanistic insights and facilitates early dose
selection. In addition, population PK/PD modeling can
help understand the critical PK characteristics and population-level covariates [20].
Physiologically-based pharmacokinetic (PBPK) modeling presents the pharmacokinetic behavior of a compound
in the body and predicts the ADME of natural or synthetic
substances in humans and other species.
Physiologically based pharmacokinetic/pharmacodynamic (PBPK/PD) models connect drug information with
prior knowledge of the physiology and biology at the
organism level to provide a mechanistic representation of
the drug in biological systems [21]. PBPK models consider
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different organs and tissues, and assist in obtaining quantitative characterizations of concentration–time profiles in
the individual compartments [22]. This modeling approach
can be utilized to understand tissue-specific PK and PD and
estimate drug interaction risks [20].
According to a survey across 50 pharmaceutical companies, the industry has a vague definition of QSP [13].
Although this survey showed that most pharmaceutical
companies used the QSP term to describe their modeling
approaches, a significant number of companies used other
terms for mentioning their modeling activities. Therefore,
to accelerate improvements in drug discoveries, one suggestion can be to use fixed terminologies that assist in
studying and investigating QSP models. The aforementioned study also showed that the most common applications in this field are related to generating and testing
hypotheses, optimizing doses or regimens, predicting
clinical efficacy, and identifying biomarkers suggesting
that future opportunities in the industry can be related to
the usage of QSP modeling for evaluating safety and
decision-making [13].

QSP modeling approaches
Pharmaceutical companies and academia utilize various
approaches for drug target discovery [13, 23]. Several
modeling approaches for QSP have been developed,
including statistical (Bayesian), Boolean, temporal (ordinary differential equations), spatio-temporal (partial differential equations), agent-based, integrative, empirical
curve fitting, and machine learning that enable integrating
molecular pathways with clinical results and pharmacology
[24]. Incorporating quantitative temporal and spatial
information in QSP models can provide more accurate
predictions of drug discovery targets, PK/PD relationships,
and clinical results [24]. Many published QSP models are
constructed as multi-compartment nonlinear systems of
ordinary differential equations (ODE) [25].
Recently, a diversity of software platforms have been
employed to assist in developing QSP models [23, 26],
such as Simbiology and toolboxes in MATLAB [27]; The
R-based packages nlmixr [23], mrgsolve [28], RxODE
[29], nlme [30], and Cell Collective platform [31–33];
Based on our review across 51 models, we note that the
MATLAB environment and tools are more popular among
QSP modelers [34–47].
Studies of QSP methodologies show that developing,
testing, and documenting QSP models require standardization to improve the reproducibility and reusability of
these models, which affect the potential impact of this
approach in academia and industry [48]. Because QSP is a
multidisciplinary field, the development of such models
demands teamwork and collaboration of different

Journal of Pharmacokinetics and Pharmacodynamics

individuals such as modeling engineers, biologists and
clinicians, data programmers, statisticians, software engineers, and PK/PD scientists [49].
While standard workflows utilizing QSP continue to
evolve [26], the general QSP workflow can be summarized
in three main steps [49]:
Model scope The first step is to define the therapeutic
field and objectives of the model by providing the physiological pathway map, which presents the incorporation of
the biological and pharmacological processes associated
with the model’s scope [49].
Model development Since any modeling task requires
some form of data, this step starts with converting raw data
to a suitable format. In this step, a modeler collects prior
models, clinical and non-clinical data and develops mathematical descriptions of the processes and compartments
involved in the interplay between drugs and the pathophysiology. Model development encompasses steps that
can be categorized into standardizing and exploring data,
parameter estimation, and simulation/analysis [26, 49, 50].
Model Qualification The modeling engineer calibrates
the QSP model to relevant data from target patient populations. This step is related to collecting appropriate clinical data in patient populations that will qualify the model
and calibrating the model at relevant scales of physiology
and time [49].

Methods
Literature search
We surveyed recent articles for QSP models available in
PubMed and published between 2019 and 2021 to identify
relevant studies, providing a repository for categorizing
and evaluating different research studies in this field.
PubMed search term ‘‘(‘‘Quantitative Systems Pharmacology’’ OR ‘‘QSP’’) AND Model*’’ (in April 2021) resulted
in 148 publications.
For QSP models, we excluded reviews and methodology-focused publications from the PubMed search results
during the manual literature mining process. We selected
original QSP studies that constructed QSP models utilizing
clinical and experimental data, resulting in a total of 50
publications. After reviewing these models, we associated
Medical Subject Headings (MeSH) terms and IDs [51] to
each model. We categorized them based on their therapeutic fields (Table 1) while including various properties of
the studied disease and model. We also explored the
application of machine learning (ML) methods in QSP
modeling and addressed modeling approaches that benefited from ML applications.

Considering the Pubmed search term results and manual
literature mining to find relevant studies, for this review,
we were able to gather and analyze a resource addressing
recent original QSP researches and their applications in
different diseases, which provides an insight into potential
future directions of QSP studies.

Results
Categories of recently published original QSP
models
We categorized original QSP models based on different
properties after the PubMed literature search. Because the
biological questions motivating a study play a critical role
in selecting the methodology and other properties of the
project, we classified the corresponding publications from
the most to the least represented biological field that utilized QSP models in the last three years. This analysis can
assist in summarizing domains that have been intensively
investigated in QSP and help find areas that need to be
explored by QSP approaches. Table 1 presents the literature mining results for recent QSP model original publications between 2019 and 2021, including the name,
PubMed ID, title, the year of publication, a MeSH term,
and a unique ID associated with each based on the
underlying biological question. We specifically utilized
MeSH terms and unique IDs, official words or phrases
selected to represent particular biomedical concepts.
We found that 24 different diseases categorized in nine
major disease areas are represented by the 51 identified
QSP model (Fig. 1). Below we describe several QSP
applications to different biological questions for the top
three categories: Immuno-oncology, nutritional and metabolic diseases, and nervous system diseases. The models
described in these categories were identified with n#
referring to Table 1.

Immuno-oncology (IO)/neoplasms QSP models
According to the World Health Organization, cancer is
among the preeminent diseases worldwide, causing globally 10 million deaths in 2020. The most frequent cancer is
breast cancer (2.26 million cases), but the most lethal is
lung cancer, with 1.8 million deaths and nearly 2.21 million cases in 2020. In the last decade, understanding the
cancer tumor microenvironment (TME) and immunosurveillance has led to promising strategies that can harness
immune cells to fight cancer [52]. Many immunotherapies
focus on the immune T cell population for their cytotoxic
function and anti-tumoral response. Current main
immunotherapies include immune checkpoint inhibitors
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Table 1 Summary of the literature mining results for recent QSP model original publications
Model
#

PubMed
ID

Title

Field: MeSH term [MeSH unique ID]

Year

1

33938166

Beyond the single average tumor: Understanding IO Combinations
using a clinical QSP model that incorporates heterogeneity in
patient response [72]

Neoplasms: melanoma [D008545]

2021

2

33389550

A quantitative systems pharmacological approach identified
activation of a JNK signaling pathway as a promising treatment
strategy for refractory HER2 positive breast cancer [68]

Neoplasms: breast neoplasms [D001943]

2021

3

33653032

Dynamical systems analysis as an additional tool to inform
treatment outcomes: the case study of a quantitative systems
pharmacology model of immuno-oncology [64]

Neoplasms [D009369]

2021

4

33579739

Quantitative systems pharmacology model predictions for the
efficacy of Atezolizumab and nab-paclitaxel in triple-negative
breast cancer [34]

Neoplasms: breast neoplasms [D001943]

2021

5

32681519

Model-informed drug development of the masked anti-PD-L1
antibody CX-072 [146]

Neoplasms [D009369]

2021

6

32533708

The timing of cyclic cytotoxic chemotherapy can worsen
neutropenia and neutrophilia [147]

Neoplasms [D009369]

2021

7

33797208

Quantitative systems pharmacology model of thrombopoiesis and
platelet life-cycle, and its application to thrombocytopenia based
on chronic liver disease [35]

Digestive system diseases: liver diseases
[D008107]

2021

8

32822108

A dynamic quantitative systems pharmacology model of
inflammatory bowel disease: part 1—model framework [36]

Digestive system diseases: inflammatory
bowel diseases [D015212]

2021

9

32822115

A dynamic quantitative systems pharmacology model of
inflammatory bowel disease: part 2—application to current
therapies in Crohn’s disease [37]

Digestive system diseases: inflammatory
bowel diseases [D015212]

2021

10

33368935

A model-based approach to investigating the relationship between
glucose-insulin dynamics and dapagliflozin treatment effect in
patients with type 2 diabetes [77]

Nutritional and metabolic diseases: diabetes
mellitus, type 2 [D003924]

2021

11

33938131

Systematic in silico analysis of clinically tested drugs for reducing
amyloid-beta plaque accumulation in Alzheimer’s disease [80]

Mental disorders: alzheimer disease
[D000544]

2021

12

33870137

Impact of sex and pathophysiology on optimal drug choice in
hypertensive rats: quantitative insights for precision medicine
[134]

Cardiovascular diseases: hypertension
[D006973]

2021

13

33128209

The influence of haemostatic system maturation on the dose–
response relationship of unfractionated heparin [148]

Cardiovascular diseases: myocardial
infarction [D009203]

2021

14

33091173

Predicted cardiac hemodynamic consequences of the renal actions
of SGLT2i in the DAPA-HF study population: a mathematical
modeling analysis [149]

Cardiovascular diseases: heart failure
[D006333]

2021

15

33894014

A mathematical model to identify optimal combinations of drug
targets for Dupilumab poor responders in atopic dermatitis [150]

Congenital, hereditary, and neonatal
diseases and abnormalities: dermatitis,
atopic [D003876]

2021

16

33205613

Investigational treatments for COVID-19 may increase ventricular
arrhythmia risk through drug interactions [38]

Infections: COVID-19 [D000086382]

2021

17

33308018

Development of a quantitative systems pharmacology model of
chronic kidney disease: metabolic bone disorder [20]

Male/female urogenital diseases-urologic
diseases: kidney diseases [D007674]

2021

18

33615174

Quantitative systems pharmacology modeling of PBMChumanized mouse to facilitate preclinical immuno-oncology drug
development [63]

Neoplasms [D009369]

2021

19

32859743

Combination therapy with T cell engager and PD-L1 blockade
enhances the antitumor potency of T cells as predicted by a QSP
model [39]

Neoplasms: colorectal neoplasms
[D015179]

2020

20

32701980

An in vitro quantitative systems pharmacology approach for
deconvolving mechanisms of drug-induced, multilineage
cytopenias [40]

Neoplasms [D009369]

2020
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Table 1 (continued)
Model
#

PubMed
ID

Title

Field: MeSH term [MeSH unique ID]

Year

21

32618119

QSP-IO: a quantitative systems pharmacology toolbox for
mechanistic multiscale modeling for immuno-oncology
applications [41]

Neoplasms [D009369]

2020

22

32533270

A quantitative systems pharmacology model of T cell engager
applied to solid tumor [42]

Neoplasms: lung neoplasms [D008175]

2020

23

32493951

Neoplasms: prostatic neoplasms [D011471]

2020

24

32158754

A QSP model of prostate cancer immunotherapy to identify
effective combination therapies [43]
Conducting a virtual clinical trial in HER2-negative breast cancer
using a quantitative systems pharmacology model with an
epigenetic modulator and immune checkpoint inhibitors [44]

Neoplasms: breast neoplasms [D001943]

2020

25

31729169

Predicting in vivo efficacy from in vitro data: quantitative systems
pharmacology modeling for an epigenetic modifier drug in
cancer [45]

Neoplasms [D009369]

2020

26

31822515

A quantitative systems pharmacology model for the key
interleukins involved in Crohn’s disease [46]

Digestive system diseases: crohn disease
[D003424]

2020

27

33085977

Mechanistic evaluation of the effect of sodium-dependent glucose
transporter 2 inhibitors on delayed glucose absorption in patients
with type 2 diabetes mellitus using a quantitative systems
pharmacology model of human systemic glucose dynamics [75]

Nutritional and metabolic diseases: diabetes
mellitus, type 2 [D003924]

2020

28

32543789

A physiologically-based quantitative systems pharmacology model
of the incretin hormones GLP-1 and GIP and the DPP4 inhibitor
sitagliptin [78]

Nutritional and metabolic diseases: diabetes
mellitus, type 2 [D003924]

2020

29

32064793

Differentiating the sodium-glucose cotransporter 1 inhibition
capacity of canagliflozin vs. dapagliflozin and empagliflozin
using quantitative systems pharmacology modeling [73]

Nutritional and metabolic diseases: diabetes
mellitus, type 2 [D003924]

2020

30

32419339

Leveraging quantitative systems pharmacology approach into
development of human recombinant follistatin fusion protein for
Duchenne muscular dystrophy [151]

Nervous system diseases: muscular
dystrophy, Duchenne [D020388]

2020

31

32558397

A quantitative systems pharmacology model of Gaucher disease
type 1 provides mechanistic insight into the response to substrate
reduction therapy with eliglustat [152]

Nervous system diseases: Gaucher disease
[D005776]

2020

32

33016912

Simulating the effects of common comedications and genotypes on
Alzheimer’s cognitive trajectory using a quantitative systems
pharmacology approach [82]

Mental disorders: Alzheimer disease
[D000544]

2020

33

32255562

Learning from amyloid trials in Alzheimer’s disease. A virtual
patient analysis using a quantitative systems pharmacology
approach [81]

Mental disorders: Alzheimer disease
[D000544]

2020

34

32765265

Quantitative systems pharmacology model-based predictions of
clinical endpoints to optimize warfarin and rivaroxaban antithrombosis therapy [153]

Cardiovascular diseases: thrombosis
[D013927]

2020

35

32991627

Correction: higher naloxone dosing in a quantitative systems
pharmacology model that predicts naloxone-fentanyl competition
at the opioid mu receptor level [154]

Chemically-induced disorders: opiate
overdose [D000083682]

2020

36

32511528

Investigational treatments for COVID-19 may increase ventricular
arrhythmia risk through drug interactions [155]

Infections: COVID-19 [D000086382]

2020

37

31236847

A computational model of neoadjuvant PD-1 inhibition in nonsmall cell lung cancer [70]

Neoplasms: lung neoplasms [D008175]

2019

38

31375756

A QSP model for predicting clinical responses to monotherapy,
combination and sequential therapy following CTLA-4, PD-1,
and PD-L1 checkpoint blockade [47]

Neoplasms: melanoma [D008545]

2019

39

31250966

Quantitative systems pharmacology model of a masked, tumoractivated antibody [62]

Neoplasms [D009369]

2019

40

31165304

Correction to: a translational quantitative systems pharmacology
model for CD3 bispecific molecules: application to quantify T
cell-mediated tumor cell killing by p-cadherin LP DART [61]

Neoplasms [D009369]

2019
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Table 1 (continued)
Model
#

PubMed
ID

Title

Field: MeSH term [MeSH unique ID]

Year

41

30990958

Quantitative systems pharmacology model of chimeric antigen
receptor T-cell therapy [59]

Neoplasms [D009369]

2019

42

31299262

PBPK modeling-based optimization of site-specific chemophotodynamic therapy with far-red light-activatable paclitaxel
prodrug [156]

Neoplasms [D009369]

2019

43

31,218,069

In silico simulation of a clinical trial with anti-CTLA-4 and antiPD-L1 immunotherapies in metastatic breast cancer using a
systems pharmacology model [157]

Neoplasms: Breast Neoplasms [D001943]

2019

44

30,898,866

Combining multiscale experimental and computational systems
pharmacological approaches to overcome resistance to HER2targeted therapy in breast cancer [158]

Neoplasms: breast neoplasms [D001943]

2019

45

30,759,154

Quantitative systems pharmacology of interferon-alpha
administration: a multi-scale approach [159]

Digestive system diseases: liver diseases
[D006505]

2019

46

31,292,220

Comparative quantitative systems pharmacology modeling of antiPCSK9 therapeutic modalities in hypercholesterolemia [160]

Nutritional and metabolic diseases:
hypercholesterolemia [D006937]

2019

47

31,423,699

Comparison of the urinary glucose excretion contributions of
SGLT2 and SGLT1: a quantitative systems pharmacology
analysis in healthy individuals and patients with type 2 diabetes
treated with SGLT2 inhibitors [76]

Nutritional and metabolic diseases: diabetes
mellitus, type 2 [D003924]

2019

48

30,443,840

Benchmarking renin suppression and blood pressure reduction of
direct renin inhibitor Imarikiren through quantitative systems
pharmacology modeling [161]

Cardiovascular diseases: hypertension
[D006973]

2019

49

31,494,805

A physiologically motivated model of cystic fibrosis liquid and
solute transport dynamics across primary human nasal epithelia
[162]

Respiratory tract diseases: cystic fibrosis
[D003550]

2019

50

30,869,201

Translational assessment of drug-induced proximal tubule injury
using a kidney microphysiological system [163]

Male/female urogenital diseases-urologic
diseases: kidney diseases [D007674]

2019

Fig. 1 The recently published
QSP models and their disease
areas. The bar chart presents the
number of articles published
between 2019 and 2021 for
developing original QSP
models. Categorizing these
articles based on the biological
questions they focused on
(presented by their MeSH
terms), revealed that most
models are related to neoplasms
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(CPIs) and chimeric antigen receptor T cells (CAR-T) [53].
These immunotherapies used in several clinical trials show
tremendous response to a wide range of solid and blood
neoplasms.
Immune checkpoints regulate the immune system and
are principal targets for cancer immunotherapy in different
cancer types [54, 55]. FDA-approved CPIs target CTLA-4,
PD-1, and PD-L1 to prevent T cell inhibition by cancer
cells. Blocking these receptors increases the activation and
proliferation of effector cells following stimulation and
antigen recognition, and consequently, is more effective to
remove cancer cells [47]. CAR-T, however, is a cellular
therapy that employs genetic modifications of autologous T
cells to maximize tumor antigen recognition and intracellular signaling pathways in T cell activation. Despite the
enthusiasm around these strategies, they have been associated with unique side effects, such as autoimmune reactions, lethal cytokine release, immune cell dysfunction, and
organ failures [56]. In addition to immunotherapies, other
strategies focus more on the cancer side, such as identifying tumor antigens or neoantigens expressed solely by
cancer cells or developing small molecules that target the
signaling landscape for more personalized approaches with
minimal side effects. Nevertheless, these therapies exhibit
several challenges (e.g., efficacy, heterogeneity in
response, drug resistance, etc. [57]) that need to be
addressed to maximize immune response and minimize
lethal side effects. We first describe immunotherapies aided
with QSP models, and we later categorize studies based on
cancer type.

Immunotherapies
In the case of cellular therapy, model #41 addresses the
complex relationships between CAR-T cell doses and the
magnitude of cytokine release syndrome (CRS), one of the
side effects following CAR-T cell therapy [58]. Interestingly, this quantitative model indicates that CAR-T injection does not cause severe CRS; however, the magnitude of
cytokines at the baseline operates as an auspicious accelerator of CRS after CAR-T administration. Thus, this tool
may serve as a personalized model of CAR-T cell therapy
to interrogate dosing and clinical toxicity [59].
Bispecific antibodies, a new generation of engineered
antibodies that can simultaneously bind two different
antigens—one side to a tumor antigen and the other side to
immune cells—has emerged as a promising novel therapy
for cancer treatment [60]. Because T cells are key effector
cells in immune response, a potent procedure used CD3,
the main marker on the T cell population, to engineer a
bispecific T cell engager (TCEs) promoting cytolytic
synapse with cancer cells [61]. The crosslinking of the
different protagonists through CD3 bispecific targeting

tumor antigen, P-cadherin (PF-06671008), has been
investigated by a QSP model #40 to quantify the relationship of the tripartite partners (drugs-T cells-tumor
cells) in vivo. The model predicted that the number of T
cells and P-cadherin expression are crucial for clinical
efficiency as the half-life of PF-06671008 only lasts one
day. Therefore, such a model can predict and optimize the
CD3 bispecific technology into the clinics for human PB/
PK prediction.
Model #25 investigated molecular cancer therapy; this
PK/PD model describes the efficiency of ORY-1001, a
small molecule inhibitor of LSD1—lysine-specific histone
demethylase that acts as an epigenetic regulator in cancer.
This predictive model examined the ORY-1001 pharmacodynamic response and response durability associated
with tumor growth across multiple doses. The model was
able to predict in vivo drug efficacy extrapolated exclusively from in vitro data. Such a mechanistic approach
could reduce the use of animal models, the cost and time in
drug development [45]. In another study that addresses
drug therapies, Stroh et al. model the activatable antibody,
Probody therapeutic (Pb-Tx), designed to keep the antigenbinding site of engineered antibody masks until local proteolytic activation in disease tissue. Model #39 integrated
the in vitro and in vivo PK/PD effects of both prodrug
CD166 and pharmacological properties for rational design
and clinical translation. The QSP model predictions proposed a greater absorption of Pb-Tx than parental antibody
and emphasized that the antibody masking strength can
modulate the molecule’s absorption in desired sites, such as
the tissue or the peripheral circulation. As a result, this
study utilized interesting approaches to customize Pb-Tx
infiltration to desired sites of tumor niches instead of a
healthy environment [62].
Another study presents a QSP model #18 of humanized
mice [63]. Here, the authors modeled the interactions
between tumor growth, T cells, cytokine secretion, immune
checkpoint expression, and drug inoculation using experimental data from a xenograft mouse model. The critical
aspect of such a model is that it can aid in extrapolating
dose conversion between animals to humans, where often
therapeutic dose translation from the rodent system to
human fails [63].
The tumor microenvironment (TME) is an essential
aspect of cancer development as it participates in survival
needs, drug resistance and installs an auspicious immunosuppressive environment [8]. Several studies investigated
the dynamic interplay between immune-mediated TME
and immunotherapy treatment. Model #20 examines cellular communication and TME crosstalk by studying
myelosuppression, a severe side-effect of anti-cancer
therapies. To improve the understanding of drug-induced
myelosuppression, Wilson et al. produced a QSP model of
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hematopoiesis in vitro to quantify the effects of anti-cancer
agents on multiple hematopoietic cell lineages [40]. Model
#21 is an open-source and expandable modeling IO platform that integrates tumor-T cell crosstalk in response to
different combinatorial immunotherapy. The QSP tool
integrates several critical modules of TME: a cancer
module (tumor size and tumor antigen), dendritic cell as
antigen-presenting cells, a T cell module (immunosuppressive regulatory T cell, cytotoxic and non-cytotoxic T
cells), checkpoint module, and a pharmacokinetics module
illustrating TME behavior upon therapeutic strategies [41].
Also, the model #3 utilized a QSP model to reproduce the
main component of interaction between tumor and immune
system to model TME response upon combination of
radiation and immunotherapy [64]. These complex QSP
frameworks can be utilized as clinical platforms to evaluate
the dynamics of therapy responses at a larger scale than at
the individual level.
Breast neoplasms
In breast cancer (BC), human epidermal growth factor
receptor 2 (HER2) is a neoantigen protein that can promote
the growth of cancer cells [65]. HER2-positive BC is an
aggressive cancer subtype prevalent in 20% of cases.
Despite improvements in anti-HER2 therapies, treatment
resistance remains a clinical challenge [66].
Wang et al. proposed two different dynamical models
(#24 and #2) of the TME to address the efficacy of existing
therapies in different types of BC. For HER2-negative BC,
they proposed a QSP model (#24) for a virtual clinical trial
with immune checkpoint therapy in association with an
epigenetic modulator. The authors integrated different
modules describing immune activation, suppression, and
trafficking into four separate compartments (lymph node,
central, peripheral, and tumor site) and PK/PD of two
therapeutic agents [44]. Their second (similarly constructed) model (#4) focuses on triple-negative breast
cancer. This BC type is defined by the lack of three
receptors (estrogen, progesterone receptors, and low HER2
expression). It classifies as highly invasive with limited
treatment and poor outcomes [67]. The authors developed a
virtual patient cohort of atezolizumab (anti-PD-L1) and
nab-paclitaxel treatments for this cancer to identify
immune biomarkers and optimal treatment for clinical trials [34].
The QSP model #2 addresses drug resistance by evaluating the efficacy of lapatinib (LAP), abemaciclib (ABE),
and 5-fluorouracil individually and in combination using
trastuzumab-resistant HER2-positive BC cell line. Their
findings suggest synergistic effects between ABE and LAP
while showing the impact of the triple combination therapy
on tumor cell viability [68]. Overall, both models address
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the dynamics of tumor-immune-drug interaction for a virtual clinical trial to provide guidelines in drug development
and clinical regiment design.
Colorectal neoplasms
Previous studies on bispecific TCE cited above led to the
construction of a QSP model, combining TCE and immune
checkpoint inhibitor, anti-PD-L1, with similar modules
described in the Breast neoplasm section [34, 44]. They
predict that the efficacy of treatment is dictated by the
patient’s variability and unique characteristics. This model
not only aids TCEs and immune checkpoint strategies but
also is an interesting tool for precision medicine initiatives
[39].
Lung neoplasms
In lung cancer, anti-PD-1 treatments show promising
results in the survival rate of patients with advanced nonsmall-cell lung cancer [69]. The QSP model #37 integrated
dynamic modules of tumor growth, antigen processing and
presentation, T cell activation and trafficking, anti-PD-1,
and antibody kinetic responses. The model predicted that
the density of anti-tumoral effector T cells in the blood
correlated with a better response to therapy than the density
of pro-tumoral regulatory T cells [70]. Later Ma et al.
extended this model to TCEs as a single therapy to explore
the dynamic of inter-cellular interactions in the tumor
microenvironment and identify immune biomarkers. This
study predicted that indicators of responders versus nonresponders to TCE therapies depend highly on the patient’s
response and stage of disease (e.g., Non-responders, partial
or complete response, stable or progressive disease conditions) [42].
Melanoma
This is a severe skin cancer derived from melanocytes,
melanin-producing cells. Located in the bottom layer of the
skin, cancerous melanocytes are likely to metastasize to
any part of the body [71]. Two models address CPIs in
melanoma cancer. Model #38 simulates CTLA-4, PD-1,
and PD-L1 therapies with varying modes of treatment
administration (single, dual, or sequential) to evaluate the
optimal parameter for melanoma treatment. The dynamic
response of their virtual patient model reproduced data
from real clinical trials. The model also predicted the
median response of each therapy and defined the physiological range of virtual responders for each combination
[47]. Milberg et al. address the efficacy of a combination
checkpoint therapy consisting of pembrolizumab (antiPDL1) and ipilimumab (anti-CTLA4) in metastatic
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Nutritional and metabolic diseases

The QSP model indicated that only canagliflozin could
inhibit renal SGLT1, resulting in identifying a critical
therapy design to maximize the SGLT2 inhibitory effect
[73]. Because glucose accumulation depends on insulin,
model #10 considers glucose-insulin dynamics in the short
and long-term under dapagliflozin treatment. According to
this model, dapagliflozin is more beneficial to patients with
more inadequate glycemic control by insulin [77]. Another
model (#28) focuses on several protagonists in glucose
levels after food consumption [78]. The incretin hormones,
glucagon-like peptide-1 (GLP-1), glucose-dependent insulinotropic polypeptide (GIP) catalyzed by enzyme dipeptidyl-peptidase 4 (DPP4), and the neutral endopeptidase
(NEP) stimulate insulin release to lower glucose. By
modeling GLP-1 and GIP dynamics, and PK/PD of DPP4
inhibitors, model #28 showed that inhibition of DPP4
occurs in a dose-dependent manner. Still, the highest dose
of DDP4 inhibitor stimulated a high GLP-1 secretion,
suggesting the triggering of alternative pathways upon
DPP4 inhibition [78].

Diabetes mellitus, type 2

Nervous system diseases

Type 2 diabetes mellitus (T2DM), commonly known as
type 2 diabetes, is a metabolic disorder translated by an
aberrant accumulation of glucose in the blood due to a
defect of insulin function and expression [73]. Different
T2DM QSP models described below focused on drugs that
could lower plasma glucose and filter it through other
organs.
A recently approved class of antidiabetic medications
includes gliflozins that target sodium-glucose co-transporter (SGLT), a class of receptors expressed in the kidney
and small intestine and responsible for more than 80% of
glucose reabsorption [74]. These drugs decrease glucose by
increasing urine secretion and blocking renal re-consumption [8]. In the first model (#27), Mori-Anai et al. addressed
the inhibitory action of three different SGLT2 inhibitors
after food consumption with a model called human systemic glucose dynamics (HSGD) integrating glucose
metabolism, intestinal uptake, and renal reabsorption. The
model provided a quantitative estimation of drugs’ effect
on dynamic glucose absorption after food consumption
[75]. In another study, a QSP model (#47) investigated
SGLT1 and SGLT2 activity in renal glucose circuits and
estimated the PK/PD of SGLT2 inhibitors using clinical
data of healthy and T2DM patients. Interestingly, the
model showed that under SGLT2 inhibition, SGLT1 action
increased, indicating compensatory relationships between
SGLT receptors and an adverse effect of the drug selection
[76]. Later, Sokolov et al. utilized this model (#29) to
address SGLT1 inhibition in response to SGLT2 gliflozins
inhibitors (dapagliflozin, empagliflozin, and canagliflozin).

Alzheimer’s disease (AD) is a slow and irreversible
degenerative disorder that leads to progressive neurocognitive dysfunction. One of the histological characteristics
of AD is the formation of amyloid plaque due to the
accumulation of insoluble extracellular amyloid-beta (Ab)
that causes inflammation and neurotoxicity [79]. Targeting
the Ab pathways is one of the main therapeutic strategies to
slow down degenerescence; however, many clinical trials
fail due to several reasons, including patient heterogeneity,
disease stage, treatment timing, ineffective drug penetration, and mechanism of action. To explore Ab therapy
failures, Madrasi et al. constructed a QSP model of the Ab
pathways with three relevant drugs (elenbecestat, verubecestat, and semagacestat) and four anti-Ab monoclonal
antibodies (aducanumab, crenezumab, solanezumab, bapineuzumab). Their model (#11) predicted that among the
different monoclonal therapies, aducanumab and bapineuzumab could induce the fastest plaque reduction, while
drug molecules promote slow reduction and their efficiency
depends on plaque turnover formation [80].
Model #33 was used to simulate a clinical trial using
aducanumab combined with different genotypes of common variants affecting cognitive function (apolipoprotein
E, Catechol -O -methyl Transferase, and 5-HT transporter
genotypes). This study highlighted the variability of clinical response between phase II and III, determined mainly
by the different variants and baseline Ab peptide accumulation [81]. Similarly, another study focused on the
same variants under benzodiazepines, antidepressants, and
antipsychotics drug treatments [82]. Model simulations

melanoma while taking into account lesions used for
melanoma immunogenicity diagnosis. The model showed
that combination therapy is significantly more efficient for
intermediate lesions than non- or high metastatic lesions
[72].
Prostatic neoplasms
The ODE-based model #23 explores castration-resistant
prostate cancer, for which therapies are still non-conclusive
[43]. This study presents a QSP model of prostate cancer
immunotherapy, integrating different immune cells, tumor
compartments, and seven treatments. Among numerous
treatment combinations, the authors found that dual association of cancer vaccine and immune checkpoint blockade
are the most effective combinatorial immunotherapy for
subjects associated with androgen-deprivation therapy
resistance.
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indicated, once again, variability of response between
baseline and mild stage of AD under different regiments.
In summary, we reviewed examples of recent QSP
models across major disease areas. Notably, many of these
studies focus on maximizing drug design, therapeutic
strategies, understanding the dynamic of drug-target
interaction at the system, finding optimal dosage,
addressing toxicity and potential adverse side effects.
Altogether, QSP is a growing platform in drug development with much potential as an integral approach to reconciling drug safety and clinical patients’ response to
therapy.

Machine learning applications in QSP modeling
The staggering amount of data generated with recent
technologies demands integrative approaches to address
the pharmacological challenges more efficiently. The ‘‘big
data’’ field aims to analyze information from datasets
containing complex or extensive amounts of information
[83]. An example of big data used for drug discovery is
observational data such as Electronic Health Records
(EHR), which encompasses patients’ unique medical
characteristics such as laboratory results, comorbidities,
treatments, and observed effects [84]. In drug development,
machine learning has been used as part of automated
pipelines to guide and accelerate preclinical wet-lab
experiments, drug discovery, and clinical trials [83, 85]. In
fact, there are opportunities to apply ML methods in nearly
all stages of drug discovery and development [85]. For
example, we can utilize ML to identify and validate novel
targets [86, 87], predict treatment responses [88], discover
biomarkers [89], predict disease progression [90] degeneration [91], and risk factors [92, 93], design and optimize
small-molecule components [94], and improve analyses of
high-throughput imaging in computational pathology [85]
89. ML can also optimize the drug candidate discovery
field by predicting desirable physicochemical characteristics,
pharmacokinetics,
safety,
and
efficacy
[20, 83, 95–100].
In this section, first, we briefly explain the basis of ML;
we refer readers to the recent publications on ML methods
[83, 101] for detailed information and additional relevant
studies. Second, we review recent applications of ML in
drug discovery and development. Finally, we provide some
examples of recent QSP efforts that benefited from
machine learning methods.

Machine learning
ML methods can be categorized into two groups: Supervised learning, which uses labeled data (the goal is to
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‘‘predict’’), and unsupervised learning, which deals with
unlabeled data (the goal is to ‘‘explore’’) [102].
Supervised ML algorithms require input data sets to be
split into a ‘‘training’’ and a ‘‘test’’ data set. Model training
fits the model to the training data set, and the trained ML
model can then be validated using the test data set. The
validated ML model can then be utilized to make predictions or decisions based on the new data set covariates
[103]. Several algorithms have been developed in this field,
such as linear and logistic regression, ridge regression,
decision trees, random forest, gradient boosting, neural
networks, and genetic algorithms [104–106]. Data sets that
contain both covariates and outcomes are ‘‘labeled’’ and
used in supervised ML.
Different studies approach drug discovery with supervised learning techniques such as regression analysis
methods (e.g., disease and target druggability from multidimensional data [87], targets for Huntington disease [107],
identify potential cancer biomarkers [108, 109], drug sensitivity prediction [110], image-based diagnosis [111]), and
classifier methods (e.g., tissue-specific biomarkers from
gene expression signatures [89], target druggability based
on PK properties and protein structure [112, 113]).
Supervised learning methods also enable the modeling
of response surfaces for estimating individualized patient
outcomes. One way to accomplish this is to fit a singleoutput model with the treatment as an input feature, making it less flexible and providing the same outcome model
for treated and untreated patients. Another approach is to fit
two separate supervised models for different treatments,
which provides more flexibility in estimating patient outcomes [114].
Unsupervised ML includes the covariates but not the
outcomes. This technique is used to identify patterns and
associations between data points. K-means and hierarchical
clustering are examples of the algorithms widely used in
unsupervised ML [83]. Unsupervised clustering methods
also have been used for drug discoveries such as de novo
molecular design [115], deep feature selection for
biomarkers [116], feature reduction in single-cell data to
identify cell types [117], and biomarkers [118].
ML-facilitated causal inference can estimate the effects
of single/multiple or time-dependent treatments on patient
outcomes. Various types of data can be used for training
ML models to evaluate treatment effects such as clinical
data (e.g., age, sex, genetic information, laboratory measurement), type of treatment (e.g., binary treatment, single
treatment, or multiple treatments), patient outcomes (e.g.,
survival probability, multiple outcomes), and treatment
decisions (e.g., optimal single/combinatorial treatment,
optimal dosage). As a result, causal inference methods can
assist physicians in decisions about the treatment benefit,
treatment options, and dosages [114].
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Integration of QSP and ML
Developing methodologies to integrate clinical data such as
EHR or biological data sets (e.g., human genetic information in large populations, omics profiling of healthy and
not healthy individuals) with QSP models provide the
opportunity for additional progress in the QSP field. Below,
we provide examples of efforts that integrated QSP models
with ML methods.
Recent studies illustrate the benefits of integrating ML
approaches with mechanistic modeling in curation, optimization, parameter estimation, and simulations of QSP
models that can be computationally costly [114, 119]. For
example, Hartmann et al. presented a predictive ML model
to assist in optimizing antithrombotic therapy [120]. For
this study, routine clinical data were gathered from 479
patients during therapeutic antithrombotic drug monitoring.
A QSP model of coagulation network was developed based
on a humoral coagulation model [121] to observe the effect
of rivaroxaban, warfarin, and enoxaparin treatment on
clotting factors levels. The authors estimated the parameters (factor rate constants, and production rates of coagulation factors) using a nonlinear programming solver. A
stiff ODE solver (a variable-step, variable-order solver
based on the numerical differentiation formulas of orders 1
to 5) was utilized for model simulation. The QSP model
predicted the steady-state effects of the rivaroxaban, warfarin, and enoxaparin treatment on clotting factor levels.
For example, the model predicted that rivaroxaban did not
affect the inactivated coagulation factor levels (such as
prothrombin, protein C, protein S). Due to the variability in
individuals responding to drugs, estimating the interindividual variability is important [122]. ML methods were
used to evaluate the importance of interindividual variability. Monte Carlo simulations [123] were performed for
interindividual variability by adding 20% variability on
estimated production rates. Sobol sensitivity analysis [124]
was performed to recognize the parameters with a higher
impact on the activation of clot-dissolution under different
treatments. The model-generated predictions suggest suppressing protein C and protein S (components that regulate
blood clot formation) under treatment with warfarin compared to enoxaparin and rivaroxaban.
Illustrating the benefits of using ML to analyze information from databases and predict drug targets, Pei et al.
utilized QSP methods to provide a comprehensive study of
cellular pathways involved in 50 drugs of abuse [125]. For
this study, 50 drugs of abuse and their relative pharmacological actions were gathered. Utilizing the DrugBank
[126], the STITCH database [127] (drug/ligand-target
interaction databases), 142 known targets of these drugs
were identified. Probabilistic matrix factorization (PMF)

[128, 129] based machine learning methodology was subsequently applied to identify 48 new targets. Studies show
that the PMF model, which scales linearly with the number
of observations, can perform well on large, sparse, and
imbalanced datasets [128]. The PMF models were trained
on 11,681 drug-target interactions and 8,579,843 chemicaltarget interactions. The study evaluated and associated a
confidence score to each predicted drug-target interaction
and selected high confidence predictions, leading to the
identification of 161 novel interactions between 27 out of
the 50 input drugs and 89 targets. The authors also identified and categorized 173 human molecular pathways
associated with the drug targets from the KEGG database.
Finally, the authors examined the involvement of these
targets and pathways in predicting drug addiction. Using
ML methods, this study provided novel target predictions
and detected critical signaling modules sensing the effects
of drugs of abuse.
Another study focused on the modulation of autophagy,
an important process with cellular functions such as cell
death/survival [130]. The authors used QSP models to
investigate the mechanism of action of autophagy modulators by predicting novel drug-target reactions and
studying the drug effects using pathway/network analysis
tools. Two hundred twenty-five autophagy modulators
were collected, including various drugs such as fostamatinib, olanzapine, melatonin, and artenimol. Data collection
was performed using the DrugBank database, and the
selected modulators were manually classified into inhibitors, activators, and dual-modulators. ML was subsequently used to predict the drug-target interaction applying
the PMF algorithm [129]. Using the DrugBank database,
the PMF model was trained by 14,983 interactions between
5,494 drugs and 2,807 targets. A confidence score was
evaluated for each predicted interaction, and the predicted
interactions with high scores were selected for each drug.
This ML approach led to 368 novel drug-target interactions. Functional analysis was performed using the predicted targets to present the enriched pathways involved in
the regulation of autophagy. The study assists in new
investigations related to the mechanism of action of
autophagy modulators [130].
Coletti et al. developed the QSP model #23 of prostate
cancer immunotherapy to identify the effective drug
combinations for prostate cancer treatment [43]. The model
was calibrated, and the numerical optimization method
[131] was used for parameter estimation. The model was
used to compute the synergistic effects and predict the
percentage of tumor inhibition. A decision tree was built to
integrate the results for making predictions about potential
causality that facilitate obtaining a more comprehensive
view of the system’s behavior. They set the androgen
deprivation therapy as the root of the decision tree to
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identify efficacious treatments for castration-resistant
prostate cancer. The decision tree edges were annotated
with Bliss Combination Index value, a commonly used
correlation measure for evaluating the synergistic effects of
the therapies. The position of the nodes along the decision
tree indicated the efficacy of the possible combined therapies. The results suggest that adding immune checkpoint
blockade to cancer vaccines is the most effective combinatorial immunotherapy to inhibit tumor growth in castration-resistant prostate cancer.
Gaweda et al. presented QSP model #17 for chronic
kidney disease mineral bone disorder (CKD-MBD) [20],
where ML methods were utilized to estimate model
parameters of the differential equations representing the
CKD-MBD compartments. A better understanding of
CKD-MBD and the variability of individuals’ CKD-MBD
indications can facilitate achieving the therapeutic intentions for reducing mortality and morbidity [132]. The
CKD-MBD model was constructed by applying modifications to a previously published model [133]. The modifications include adding new components to the model and
using ML methods to estimate the parameters related to
CKD-MBD model (such as parameters in the parathyroid
gland compartment, renal phosphate reabsorption, and
smooth muscle cell compartments of model #17). The
CKD-MD model contains individual functions with
parameters that require to be estimated. Utilizing data from
5496 CKD patients, they estimated 23 parameters associated with components of the modified model. The model
fitting was performed using nonlinear least-squares
regression with the trust-region reflective algorithm. The
resulting model was validated by ten-fold cross-validation
(each fold included 30,106 training vectors and 3345
testing vectors).
Another study integrated mechanistic models with ML
to predict treatment response [134]. The authors developed
a QSP model (#12) for blood pressure regulation. High
blood pressure enhances the risk for various cardiovascular
diseases [135]. Studying the treatment response in hypertensive patients is essential since about half of the patients
do not reach adequate blood pressure control after treatment [136]. The QSP model of blood pressure regulation
was constructed to provide insight into utilizing precision
medicine in hypertension. A sex-specific virtual population
was built to consider the heterogeneity between the sexes
and within hypertension physiopathology. After constructing the sex-specific QSP model and creating the virtual population, ML methods integrated with the
mechanistic model evaluated the response to antihypertensive therapies. The authors constructed a decision tree to
identify the optimal drug class. This decision tree was
trained to predict which drug class causes the optimal
reduction in mean arterial pressure across the virtual
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population. Several variables can influence hypertension
physiopathology and the mean arterial pressure. The features of the virtual individuals include antidiuretic hormone
secretion rate, arterial resistance, renin secretion rate, the
strength of the myogenic response, aldosterone secretion
rate, renal sympathetic nerve activity, afferent arteriolar
resistance, and venous resistance, which are pathophysiological variables. The model was validated using five-fold
cross-validation [134].
Mathematical modeling can be helpful in order to estimate risks versus potential benefits when quick decisionmaking is required. For example, several proposed drugs
for coronavirus disease 2019 (COVID-19) patients were
associated with cardiac adverse events [137]. Model #16
presented cardiac risks of COVID-19 therapies using a
combination of PK and QSP modeling [38]. For this purpose, the authors investigated the potential effects of azithromycin, lopinavir, chloroquine, and ritonavir on cardiac
electrophysiology. In order to predict cardiac adverse
events, PK with the QSP model of ventricular myocytes
has been utilized. A QSP model developed by O’Hara et al.
was applied to simulate the effects of the drugs on ventricular action potentials [138]. Then, the QSP simulations’
drug concentrations were linked with patients’ free plasma
drug concentrations using PK models to simulate drug
disposition. This study predicted a greater action potential
prolongation by using the combination therapy involving
these drugs compared with drugs given in isolation. In
order to study the influence of sex and pre-existing heart
failure, models for different patient groups were developed,
and virtual populations were generated to simulate the
individual’s physiological variability. A logistic regression
analysis was performed on population outcomes to evaluate why individual cells were resistant or susceptible to
arrhythmias. Modeled ventricular myocytes were labeled
as 1 (arrhythmic dynamics) and 0 (no arrhythmic dynamics) in the simulated population. The developed logistic
model predicted the probability of arrhythmia from the
parameter values in each cell. The simulations of patient
groups suggest that women with pre-existing heart failure
are particularly susceptible to drug-induced arrhythmias.
In this section, we presented examples of applying ML
methods in different steps of QSP modeling, such as predicting treatment response, evaluating risks versus potential benefits for clinical decision-making, estimating the
model parameters, model simulation, analyzing the information from databases, and predicting drug targets. Figure 2 summarizes the potential areas in which QSP
modeling can benefit from ML methods. However, we note
that substantial opportunities exist for the integration of
QSP models with ML to further fuel pharmacometrics and
drug development in general. Hence, there is a need for
collaboration
between
statisticians,
clinical
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Fig. 2 Application of Machine
learning in supporting
challenges and limitations of
quantitative system
pharmacology

pharmacologists, QSP modelers, and ML engineers to
benefit from the full potential of using integrative approaches and extensive data resources.

Discussion
In this review, we present recent efforts utilizing mechanistic QSP models in drug development and clinical
strategies across various pathologies. Given the multidisciplinary potential of QSP methodologies, we considered
ML as a complementary tool to be used soon along with
QSP to improve empiric simulation and predictions for
drug development.
QSP is a quantitative framework that mimics the
mechanistic knowledge of biological systems. QSP
approaches can provide several advantages. First, QSP
provides a platform to assess preclinical and clinical outcomes during drug development. Second, QSP can parametrize complex molecular and cellular interactions to
evaluate the overall behavior of drug-target and drug-drug
interaction under any biological system. For example,
some I-O trials faced an increased therapy failure because
of the complex dynamic interaction between TME, drug,
and cancer cells, indicating the relevance of the development of virtual systems to comprehend such complex
cross-interaction [8]. Third, QSP can model patient cohorts
using individual patient clinical data and optimize the
clinical trial design. Fourth, the personalization of QSP
models can maximize the clinical trial design calibrated to
patients’ background variability. Finally, QSP models can
reduce the time and the cost during the drug development
during the decision-making process.

Challenges and opportunities
Despite the wide range of applications, QSP approaches
also exhibit certain limitations and challenges. With the
expansion of omics technologies, QSP rarely integrates
omics data into the framework, possibly due to the amount
of information needed to combine during model construction. Notably, the confidence of the QSP model largely
depends on experimental data available at the biological
scale of interest to parametrize the model. However,
quantitative data are often missing. The gaps can be filled
using various experimental resources that may or may not
be fully compatible with each other (e.g., by simultaneously considering data from in vitro and in vivo studies or
different animal models). Thus, integrating omics data with
QSP models will provide additional biological knowledge
to fill mechanistic and clinical data gaps during model
construction [13].
As indicated in Fig. 1, QSP approaches have focused on
a limited number of diseases. While I-O appears to leverage QSP models recently most widely, other areas of
medicine, such as transplantation management and rare
diseases, have also begun applying QSP-informed
approaches in drug discovery, clinical strategies, characterization of side effects, and set up a virtual patient cohort
to support more personalized design therapies.
Another challenge is that QSP mainly focuses on the
prominent cells or molecules and does not integrate all
biological interactions of the environment. For example,
TME supports cancer cells through direct and indirect
effects that influence drug infiltration and resistance [8].
Nevertheless, this limitation can be addressed by using
computational platforms such as Cell Collective to analyze
large-scale biological systems to predict biomarkers of
biological interactions. In addition, the Systems Biology
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Markup Language (SBML) is the most adopted standardized file format that is developed for storing computational
models in a form that various modeling platforms can
exchange [139]. However, based on a survey published in
2019, using SBML has not become a dominant approach in
QSP modeling [140]. Utilizing a standard format for QSP
models would enable the exchange and reusability of QSP
models and their collection in online repositories and
modeling platforms of mathematical models such as Cell
Collective [31] and BioModels [141]. For example, BalbasMartinez et al. illustrated the benefits of such modelsharing cyberinfrastructure by constructing and sharing
their model for inflammatory bowel diseases in the Cell
Collective platform [33].
Given their mechanistic nature, QSP models can also be
utilized to understand the normal physiological behavior of
molecules and cells in non-disease conditions. For example, Puniya et al. developed a mechanistic logical model of
T cell plasticity and discovered the potential of a hybrid T
cell population upon external cytokine stimulation [142].
Knowing the complexity of T cell biology, a recent study
integrated four different modeling approaches to build
three different scales (e.g. signaling, metabolism and cellular) capturing the essential biological phenomena of T
cell biology [143]. Understanding the importance of different T cell populations in disease, QSP models can
address the dynamic of cell development to predict
biomarkers and conditions where the cellular balance is
disrupted.
Notably, the QSP approach is often mentioned by many
modeling approaches such as PBPK and PK/PD models,
creating disparate communication between models and
corporations. Therefore, defining a clear consensus for QSP
among academia and pharmaceutical companies will
facilitate interaction between fields and accelerate drug
development strategies.

ML benefits in QSP methodologies
Mechanistic QSP models can integrate multi-layered data
and characterize mechanisms that explain the emergence of
biological function, phenomenon, or disease. However, as
QSP models grow in scope and depth, their simulations and
analyses become computationally too expensive [144]. ML
models can be highly predictive and integrate multi-modal,
multi-fidelity data relatively easily to reveal correlations
between intertwined phenomena. However, ML models
alone ignore the fundamental mechanisms behind their
predictions. The integration of these approaches can result
in a computationally efficient approach that can generate
predictions with high accuracy and identify the underlying
mechanism of the disease or its treatment [145]. With the
expansion of multi-dimensional biomedical data,
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integrative strategies are developed to exploit and process
these data to sustain a rich platform of information and
support research and development. ML provides a powerful computational approach to handle and leverage big data
to make intelligent decisions. The potential of ML in
processing big data can transform the QSP platform into
larger complex modeling systems. For example, QSP
models are built as ‘‘horizontal integration’’ systems
including structural networks (e.g., receptors, signaling
pathways, metabolic pathways, or cell types); however,
vertical integrations such as multiscale modeling (e.g.,
molecule, cells, tissue, and organs) are more challenging to
conceptualize [7]. In addition, QSP modeling requires a
human intervention to curate biological networks and literature review manually; therefore, adding ML in QSP can
reduce bias in manual curation and allow automated data
mining. Another benefit of ML to consider is parameter
estimation during the development of the QSP model. The
lack of prior knowledge and heterogeneity of data used
during QSP model development can cause modeling
uncertainty beyond the scope of biological knowledge.
Therefore, ML algorithms can calibrate an interval for
parameter estimation using robust statistical analysis to
minimize prediction uncertainties [26, 49]. ML is broadly
utilized in several fields; however, it is only now being
considered as a companion to QSP models.

Conclusion
Quantitative systems pharmacology is increasingly solicited in drug development and clinical areas. QSP has
demonstrated a positive impact in modern medicine
through understanding mechanistic pathways of drug-target
interactions, absorption, trafficking, metabolism, and side
effects. QSP can help decrease the time and cost of drug
development by systematically evaluating drug targets’
safety and efficacy. QSP can further increase its impact by
integrating with ML and expanding to many other diseases.
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41. Sové RJ, Jafarnejad M, Zhao C et al (2020) QSP-IO: A Quantitative Systems Pharmacology Toolbox For Mechanistic Multiscale Modeling For Immuno-Oncology Applications. CPT
Pharmacometr Syst Pharmacol 9:484–497. https://doi.org/10.
1002/psp4.12546
42. Ma H, Wang H, Sove RJ et al (2020) A quantitative systems
pharmacology model of T cell engager applied to solid tumor.
AAPS J 22:85. https://doi.org/10.1208/s12248-020-00450-3
43. Coletti R, Leonardelli L, Parolo S, Marchetti L (2020) A QSP
model of prostate cancer immunotherapy to identify effective
combination therapies. Sci Rep 10:9063. https://doi.org/10.
1038/s41598-020-65590-0
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